Halozyme Therapeutics, Inc. (HALO) Posts Surprise Q2 Profit
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $104.89 +1.83%
Financial Fact:
Interest and other income, net: 334K
Today's EPS Names:
SCWO, HSAI, SYRS, More
Financial Fact:
Interest and other income, net: 334K
Today's EPS Names:
SCWO, HSAI, SYRS, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q2 EPS of $0.03, $0.16 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $23.2 million versus the consensus estimate of $4.95 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
- Prenetics Global (PRE) Tops Q2 EPS by 18c
- Keysight Technologies (KEYS) Tops Q3 EPS by 59c; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
